,i #aadth ,,congress #ast ,session ,h4 ,r4 #bddc ,,in ,,the ,,house ,,of ,,representatives ,may #ai1 #bjae ,mr4 ,guthrie introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act with respect to ,,clia waiver study design guidance for in vitro diagnostics4 #a4 ,,clia waiver study design guidance for in vitro diagnostics 7a7 ,draft revised guidance ,not later than #ab months after the date of the enactment of this ,act1 the ,secretary of ,health and ,human ,services shall publish a draft guidance that-- 7#a7 revises section ,v ,demonstrating ,insignificant ,risk of an ,erroneous ,result--,accuracy of the guidance entitled ,recommendations for ,clinical ,laboratory ,improvement ,amendments of #aihh 7,,clia7 ,waiver ,applications for ,manufacturers of ,in ,vitro ,diagnostic ,devices and dated ,january #cj1 #bjjh2 and 7#b7 includes guidance on the appropriate use of comparable performance between a waived user and a moderately complex laboratory user to demonstrate accuracy4 7b7 ,final revised guidance ,the ,secretary of ,health and ,human ,services shall finalize the draft guidance published under subsection 7a7 not later than #ab months after the comment period for such draft guidance closes4